Department of Medicine, Division of Endocrinology and Metabolism, University of Perugia, Hospitals and Clinics, Piazzale Menghini 1, 06129, Sant'Andrea delle Fratte, Perugia, Italy.
Department of Medicine, Division of Endocrinology and Metabolism, University of Perugia, Hospitals and Clinics, Piazzale Menghini 1, 06129, Sant'Andrea delle Fratte, Perugia, Italy.
Nutr Metab Cardiovasc Dis. 2020 Nov 27;30(12):2389-2397. doi: 10.1016/j.numecd.2020.08.002. Epub 2020 Aug 20.
The relationship among distribution of pathological values at the Oral Glucose Tolerance Test (OGTT), metabolic risk factors and pregnancy outcomes in women with Gestational Diabetes (GDM), has not been clearly identified. We retrospectively compared metabolic and therapeutic parameters, maternal-fetal outcomes and post-partum OGTTs, with respect to the number and distribution of altered values of diagnostic OGTT in pregnancy. Secondly, we assessed whether insulin therapy predictive factors were identifiable.
This analysis included 602 pregnant women with GDM, followed in Diabetes and Pregnancy Unit of Perugia Hospital from diagnosis to childbirth. All women were diagnosed diabetic upon 75g OGTT, according IADPSG criteria. Women were divided into 3 groups, respect to distribution of diagnostic blood glucose (BG) values at OGTT: Group 1: only fasting BG (OGTT0h); Group 2: 1 and/or 2h (OGTT1-2h); Group 3: both fasting and 1 h and/or 2h (OGTT0+1-2h) BG. Pregnant women with fasting hyperglycemia at OGTT (Groups 1 and 3) had similar metabolic characteristics (weight, prevalence of obesity, gestational weight gain, HbA1c), a greater need for insulin therapy, and a higher risk of impaired glucose tolerance persistence after childbirth, as compared to Group 2. No significant differences were observed in terms of maternal and neonatal outcomes (p > 0.05), except for a greater prevalence of caesarean sections in Group 3.
The metabolic characteristics of GDM women are mirrored by OGTT values at diagnosis, but are not associated with adverse pregnancy outcomes. Intensive management and a tailored treatment of GDM improve maternal-neonatal outcomes, regardless of diagnostic values distribution and pre-gestational metabolic characteristics.
口服葡萄糖耐量试验(OGTT)的病理值分布、代谢危险因素与妊娠期糖尿病(GDM)患者的妊娠结局之间的关系尚未明确。我们回顾性比较了不同诊断 OGTT 值分布情况下的代谢和治疗参数、母婴结局以及产后 OGTT,其次,评估了胰岛素治疗预测因素是否可识别。
该分析纳入了 602 例在佩鲁贾医院糖尿病与妊娠科就诊的 GDM 孕妇,随访至分娩。所有女性均根据 IADPSG 标准在 75g OGTT 时被诊断为糖尿病。根据 OGTT 诊断血糖(BG)值的分布,将女性分为 3 组:组 1:仅空腹 BG(OGTT0h);组 2:1 小时和/或 2 小时(OGTT1-2h);组 3:空腹和 1 小时和/或 2 小时(OGTT0+1-2h)BG。与组 2 相比,OGTT 空腹高血糖的孕妇(组 1 和组 3)具有相似的代谢特征(体重、肥胖患病率、妊娠期体重增加、HbA1c),需要更多的胰岛素治疗,并且产后糖耐量受损持续存在的风险更高。在母婴结局方面(p>0.05),除了组 3 剖宫产率较高外,未观察到显著差异。
GDM 女性的代谢特征反映在诊断时的 OGTT 值中,但与不良妊娠结局无关。强化管理和个体化治疗 GDM 可改善母婴结局,无论诊断值分布和孕前代谢特征如何。